Tue, November 2, 2021
Mon, November 1, 2021
Sun, October 31, 2021
Sat, October 30, 2021
Fri, October 29, 2021
Thu, October 28, 2021
Wed, October 27, 2021

David Lebowitz Maintained (ALNY) at Buy with Decreased Target to $226 on, Oct 29th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-226-on-oct-29th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

David Lebowitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $242 to $226 on, Oct 29th, 2021.

David has made no other calls on ALNY in the last 4 months.



There are 7 other peers that have a rating on ALNY. Out of the 7 peers that are also analyzing ALNY, 3 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $108 on, Thursday, October 28th, 2021
  • Gary Nachman of "BMO Capital" Maintained at Hold with Increased Target to $196 on, Friday, August 27th, 2021
  • Edward Tenthoff of "Piper Sandler" Downgraded from Buy to Hold and Held Target at $181 on, Wednesday, August 4th, 2021


These are the ratings of the 4 analyists that currently disagree with David


  • Esther Rajavelu of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $215 on, Monday, October 4th, 2021
  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $250 on, Friday, August 13th, 2021
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $216 on, Wednesday, August 4th, 2021
  • David Lebovitz of "Morgan Stanley" Maintained at Buy with Increased Target to $234 on, Wednesday, August 4th, 2021

Publication Contributing Sources